Cyclo(Arg-Gly-Asp-D-Phe-Cys) (TFA)

Cyclo(Arg-Gly-Asp-D-Phe-Cys) (TFA)

• UNSPSC Description: Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors[1].
• Target Antigen: Integrin
• Type: Peptides
• Related Pathways: Cytoskeleton
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/cyclo-arg-gly-asp-d-phe-cys-tfa.html
• Purity: 98.59
• Solubility: H2O : 13.3 mg/mL (ultrasonic;warming)
• Smiles: O=C([C@@H](CC1=CC=CC=C1)NC([C@H](CC(O)=O)NC(CNC2=O)=O)=O)N[C@@H](CS)C(N[C@H]2CCCNC(N)=N)=O.OC(C(F)(F)F)=O
• Molecular Weight: 692.66
• References & Citations: [1]Hazenbiller O, et al. Reduction of pluripotent gene expression in murine embryonic stem cells exposed to mechanical loading or Cyclo RGD peptide. BMC Cell Biol. 2017 Nov 14;18(1):32.
• Shipping Conditions: Blue Ice
• Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
• Clinical Information: No Development Reported